Target, across the briefings
KDR across 3 cancers
KDR is on the target list of 3 of the briefings. A drug aimed at it carries an FDA label naming the disease in 3, and is approved for some indication in 3.
| Disease | Label status | Furthest stage (Open Targets) | Distinct drugs | Cell-therapy trials |
|---|---|---|---|---|
| Kidney cancer | approved here Axitinib, Cabozantinib, Lenvatinib, Pazopanib, Sorafenib, Sunitinib, Tivozanib | approved | 70 | 4 via VEGFR |
| Hepatocellular carcinoma | approved here Cabozantinib, Lenvatinib, Ramucirumab, Regorafenib, Sorafenib | approved | 70 | — |
| Gastric cancer | approved here Ramucirumab | approved | 70 | 0 via VEGFR2 |
"Approved here" means a drug Open Targets records as aimed at KDR carries an FDA label that names that disease, per the briefing's openFDA stage. "Approved elsewhere" means the drug is approved for some other indication. Stage is the furthest Open Targets clinical stage among drugs aimed at the gene, in any indication; the database is reported as it is, and it lags some approvals. Cell-therapy trials are counted on the antigen the briefing maps the gene to, from ClinicalTrials.gov.